The PE Ratio as of May 2025 (TTM) for CytoMed Therapeutics Limited (GDTC) is -13.15

According to CytoMed Therapeutics Limited’s latest financial reports and current stock price. The company's current PE Ratio is -13.15. This represents a change of 2.82% compared to the average of -12.79 of the last 4 quarters.

CytoMed Therapeutics Limited (GDTC) Historical PE Ratio (quarterly & annually)

How has GDTC PE Ratio performed in the past?

The mean historical PE Ratio of CytoMed Therapeutics Limited over the last ten years is -22.08. The current -13.15 PE Ratio has changed 5.85% with respect to the historical average. Over the past ten years (40 quarters), GDTC's PE Ratio was at its highest in in the December 2021 quarter at 0. The PE Ratio was at its lowest in in the June 2022 quarter at -3723.18.

CytoMed Therapeutics Limited (GDTC) PE Ratio by Quarter and Year

Discovering the peaks and valleys of CytoMed Therapeutics Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

CytoMed Therapeutics Limited (GDTC) Average PE Ratio

How has GDTC PE Ratio performed in the past?

The current PE Ratio of CytoMed Therapeutics Limited (GDTC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

CytoMed Therapeutics Limited (GDTC) PE Ratio vs. Peers

How is GDTC’s PE Ratio compared to its peers?

CytoMed Therapeutics Limited’s PE Ratio is less than Bionomics Limited (0), less than OKYO Pharma Limited (-0.00), greater than Candel Therapeutics, Inc. (-18541.57), less than Anebulo Pharmaceuticals, Inc. (-6.82), less than Cingulate Inc. (-5.45), less than Nascent Biotech, Inc. (-1.98), less than ProtoKinetix, Incorporated (-0.10), less than RespireRx Pharmaceuticals Inc. (-12.17), less than Silo Pharma, Inc. (-0.10), less than VG Life Sciences Inc. (-0.47), less than Monopar Therapeutics Inc. (1.00), less than Senti Biosciences, Inc. (-0.66), less than Processa Pharmaceuticals, Inc. (-0.58), less than Fresh Tracks Therapeutics, Inc. (-0.19), less than LAVA Therapeutics N.V. (6.38), less than Inhibikase Therapeutics, Inc. (-1.20), less than Sio Gene Therapies Inc. (0), less than Kaleido Biosciences, Inc. (-4.92), less than Tempest Therapeutics, Inc. (-0.49), less than null (0), less than null (-0.53),

Build a custom stock screener for CytoMed Therapeutics Limited (GDTC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CytoMed Therapeutics Limited using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

CytoMed Therapeutics Limited (GDTC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like CytoMed Therapeutics Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.